CANTICANTI home
Back to targets

Target detail

AGA

aspartylglucosaminidase

Data: Live structured evidence (Supabase)

Marker index metadata

Foundation row from public.targets — full Open Targets / ChEMBL preload remains a future operator job (Phase 8H+).

Display name: aspartylglucosaminidase

Aliases: AGA, aspartylglucosaminidase

Type / organism: protein_coding · Homo sapiens

Source: opentargets · ENSG00000038002

Index freshness: last_synced_at 2026-05-15T20:02:15.361+00:00 · updated 2026-05-15T20:02:15.842584+00:00

Disease hub (glioblastoma)Guided · AGA

Limitations & build flags

  • Read-only structured navigator
  • No clinical outcome benefit inferred
  • Trial presence does not imply success
  • Drug identity may require normalization
  • Terminated/withdrawn trials must remain visible
Target index (foundation)

This symbol is listed in public.targets (operator seed or future preload). Connector-backed sections below may still show empty states until ChEMBL / Open Targets / ClinicalTrials.gov mirror rows exist for this marker.

Glioblastoma disease hub·Guided lookup
Live structured evidence · sources

Connectors represented in loaded rows for AGA. Empty groups mean no matching rows — not a claim about biology or clinical use.

  • ClinicalTrials.govLive when indexed

    Registry mirror rows in clinical_trials when operators run the CT.gov enrichment CLI — browser never calls the registry directly.

  • Open TargetsLive when indexed

    Disease–target evidence rows when operators run enrich:opentargets (GraphQL from trusted scripts only).

Open Targets · disease–target evidence

Rows from disease_target_evidence for this symbol.

glioblastoma

literature · opentargets

ChEMBL · linked drugs (drug_targets)

Drug records tied via drug_targets — mechanistic linkage only.

No linked drug rows

When drug_targets and drugs rows exist for this symbol, they are listed here.

repoDB-style · approved-elsewhere discussion candidates

disease_drug_evidence rows on linked drugs whose evidence_type suggests approved-elsewhere discussion context.

No matching rows

Import repoDB-compatible disease–drug evidence or add structured rows to surface discussion candidates here.

ClinicalTrials.gov · trial-matched options

Mirror rows whose text fields mention this symbol — registry context only.

NCT02864368 — Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens

Status: TERMINATED · clinicaltrials.gov

Open trials hub

NCT02664363 — EGFRvIII CAR T Cells for Newly-Diagnosed WHO Grade IV Malignant Glioma

Status: TERMINATED · clinicaltrials.gov

Open trials hub

NCT03152318 — A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2

Status: ACTIVE_NOT_RECRUITING · clinicaltrials.gov

Open trials hub
CANTI signal builder · target-linked research signals

Repurposing signal rows for drugs linked to this target via drug_targets.

No research signals for linked drugs

Run the deterministic signal builder after drug_targets and source rows are present.

Caution / negative-evidence rows

Structured rows with negative evidence_direction on disease–drug or signal tables.

No negative-direction rows

When structured evidence includes explicit negative direction fields, they surface here for oncology review.

Missing evidence · row counts by source string
  • clinicaltrials.gov: 3
  • opentargets: 1
Summary row (aggregated list)

Structured evidence rows link this marker to cohort contexts when ingested — interpret as research context only.

Disease contexts

0

Linked drugs

0

Linked in dataset

0

Research signals

0

Evidence badges (illustrative)

Doctor-discussion candidate and related tags are descriptive only.

Appears in source landscapeLinked in datasetRequires oncology review
Linked research signals (list read)

Signals list: Live structured evidence (Supabase)

No matching live evidence found

When repurposing_signal rows reference this marker via linked drugs, summaries appear here.